The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of S-1 for the treatment of cytokine and/or tyrosine-kinase inhibitor (TKI) refractory metastatic renal cell carcinoma: Updated results.
Yoshihiko Tomita
Research Funding - Taiho Pharmaceutical
Nobuo Shinohara
No relevant relationships to disclose
Atsushi Mizokami
No relevant relationships to disclose
Masato Fujisawa
No relevant relationships to disclose
Katsuyoshi Hashine
No relevant relationships to disclose
Masaharu Nishikido
No relevant relationships to disclose
Masayuki Nakagawa
No relevant relationships to disclose
Hideyuki Akaza
Consultant or Advisory Role - Taiho Pharmaceutical
Taiji Tsukamoto
No relevant relationships to disclose
Seiji Naito
No relevant relationships to disclose